The first Americans to receive a COVID-19 vaccine could get it as soon as December 11 or 12, the White House vaccine czar said on Sunday.
Phase-3 trial of Covaxin is very crucial, and this is the largest clinically phase-3 trial in India, said Dr. E Venkata Rao, Principal Investigator in the Covaxin human trial to ANI on November 21.
Covaxin, developed by Bharat Biotech, is currently undergoing phase-3 trials. But an "adverse event" took place during the phase 1 trial of its coronavirus vaccine candidate in August, when a patient was hospitalised after receiving a dose of the COVID-19 vaccine. The matter, however, was not made public.
Health Minister of Haryana, Anil Vij was administered a trial dose of Covaxin, an under trial vaccine for COVID-19, at a hospital in Ambala on November 20.
Haryana Health Minister Anil Vij on Friday administered a trial dose of coronavirus vaccine candidate Covaxin, at a hospital in Ambala. He had offered to be the first volunteer for the third phase trial of Covaxin, which started in the state today.
Haryana Health Minister Anil Vij on Friday administered a trial dose of coronavirus vaccine candidate Covaxin, at a hospital in Ambala. He had offered to be the first volunteer for the third phase trial of Covaxin, which started in the state today.
Vice-Chancellor of Pt BD Sharma University of Health Sciences, (Rohtak), OP Kalra during a press conference on November 18 said that the third phase of Covaxin will start from November 20.
Dr Vijay Bhaskar, Chairman, Ethics Committee (clinical trials and research) informed about the status of COVID vaccine. He said that several vaccines are in third phase of clinical trials and common people will able to have access to them once a succ
Last month the vaccine maker said it had successfully completed interim analysis of Phase I and II trials of the vaccine and is initiating Phase-III trials in 26,000 participant.
India's own coronavirus vaccine COVAXIN developmed by Bharat Biotech could be launched as early as February 2021 after the last stage trials began a couple of weeks ago, Reuters said a senior government official has informed.
Bharat Biotech is planning to launch its vaccine for COVID-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities, a top company official said. It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.
During press conference held on October 27, ICMR DG Balram Bhargava said, "Kawasaki disease is an auto-immune disease that affects children who are less than 5 years of age.
The third phase human trial of indigenously developed COVID-19 vaccine 'Covaxin' will soon commence at the Institute of Medical Sciences (IMS) and SUM Hospital in Odisha. IMS and SUM Hospital is in the list of 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.
India's leading biotechnology company Bharat Biotech expects to launch Covaxin, its indigenously developed coronavirus vaccine, by June 2021. The Hyderabad-based firm on Friday received approval from the Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials of its vaccine with certain conditions.
Bharat Biotech, a leading vaccine maker which is developing India's own vaccine for coronavirus named COVAXIN said it has successfully completed interim analysis of Phase I and II trials and is initiating Phase-III trials in 26,000 participants.
Leading vaccine maker Bharat Biotech, which is developing India's own vaccine for coronavirus named COVAXIN has got the nod from the Drugs Controller General of India (DCGI) to conduct phase 3 clinical trials.
The inactivated virus is formulated with ViroVax's adjuvant to produce the vaccine candidate, it said. Bharat Biotech is currently conducting Phase II human trials of Covaxin after receiving approval from the Drug Controller General of India (DCGI).
Telangana Governor Dr Tamilisai Soundararajan on Tuesday said that the whole world was looking towards Hyderabad for an effective COVID-19 vaccine.
India's indigineously developed coronavirus vaccine -- Covaxin -- phase 3 trials will be starting in Punjab's three Government Medical Colleges will in collaboration with the Indian Council of Medical Research (ICMR), an official said.
The Uttar Pradesh Government has allowed the phase-3 trial of the coronavirus vaccine 'Covaxin' in Lucknow and Gorakhpur on Wednesday.
Top News
Latest News
